Living with Diabetes? Check out our site for you

Healthcare professional? This is your dedicated site.

Insulin pumps 640G

TRANSFORMING LIVES
WITH THE WORLD'S
MOST ADVANCED
INSULIN PUMP

TRANSFORMING LIVES
​WITH THE WORLD'S MOST ADVANCED INSULIN PUMP

LOOKING TO
REDUCE HBA1C IN YOUR PATIENTS?

An Insulin Pump such as the MiniMed® 640G System^ reduces HbA1C incidents in your patients. It can guide them towards better control12 by providing advanced protection from hypoglycaemic episodes13 and offering greater convenience for easier daily management of diabetes.

Introducing the MiniMed® 640G System^: it thinks22  

A patient’s glucose level depends on many factors, including diet, exercise and stress levels. The MiniMed® 640G System^ gives patients better control because, along with its exclusive SmartGuard™ technology, it does the thinking for them. By closely mimicking the way a healthy pancreas delivers basal insulin to the body it helps patients better manage their condition, making it easier for them to follow your prescribed therapy plan.

Continuous Glucose Monitoring (CGM) 

Our advanced integrated CGM makes diabetes management more informative for you and more actionable for your patients.

With Guardian™ 2 Link and Enlite™ sensor, your patients can:

  • Continuously monitor glucose levels
  • Comfortably wear the sensor for up to six days
  • Be alerted before sensor glucose is above or below user-set limits.

CGM identifies up to four times as many serious glucose incidents compared to self-monitoring with a blood glucose meter.

  • Enlite™ detects 98% of hypoglycaemic events23
  • 8 out of 10 users do not feel the Enlite™ sensor under their skin at all24
  • 8 out of 10 users feel more confident in managing their glucose levels.24

Discover whether your patient is eligible for funding from the CGM Initiative.

Learn more

Advanced protection with SmartGuard™

 

Advanced protection with SmartGuard

SmartGuard™ provides advanced protection by:

  • Preventing severe hypoglycaemic episodes 80% of the time25 by automatically stopping insulin supply when sensor glucose is predicted to approach a low limit26
  • Avoiding hyperglycaemic rebound, resuming insulin delivery when levels recover27
  • Better protecting against lows - day and night - with multiple limit settings.

Stopping insulin delivery also reduces the length and severity of low glucose levels.

  • 93% of those who used a suspend feature in their pump felt more secure managing their diabetes.28

Greater convenience

  • More informative – with the Bolus Wizard™ calculator
  • Programmable – with treatment reminders
  • Remote bolus from meter
  • Simple-to-set preset bolus and basal patterns
  • Volume-adjustable alerts.

Improved design

  • Our first Insulin Pump with a full colour auto-brightness display – for at-a-glance viewing of all settings
  • Large screen automatically adjusts to the surroundings
  • Durable and scratch resistant
  • Waterproof up to 3.6 meters for up to 24 hours – with an IPX8 waterproof rating.

Easy management for patients

The Contour® Next LINK 2.4 meter wirelessly connects to the MiniMed® 640G System^ for easier diabetes management, including:

  • Remote bolusing
    Discreetly sends bolus commands to the pump
  • Automatic transfer
    Automatically sends blood glucose values to the Bolus Wizard™, for easier bolus dosing
  • Easier sampling
    Sip-In Sampling™ technology automatically draws blood into the test chamber while Second-Chance™ sampling allows patients to add more blood if initial samples are insufficient.

Smarter tracking

The Contour® Next LINK 2.4 meter connects to Medtronic CareLink® therapy management software, allowing your patients to track their blood glucose control in greater detail.

  • Medtronic CareLink® upload - conveniently allows patients to upload both their meter and pump information to Medtronic CareLink® software, providing you with detailed logs to optimise therapy adjustments
  • Has been shown to help reduce HbA1c among patients, which can lead to reductions in complications
  • Detailed, easy-to-interpret glucose trend reports conveniently allow you to review patient events and trends.

^Components sold separately. Automated insulin delivery is made possible through combining Medtronic insulin pump and continuous glucose monitoring technology. 

12. Bergenstal RM, Tamborlane WV, Ahmann A, et al. The STAR 3 Study Group. Effectiveness of sensor-augmented insulin-pump therapy in Insulin Dependent Diabetes. N Engl J Med. 2010;363(4):311-320.

13. Garg S, Brazg RL, Bailey TS , et al. Reduction in duration of hypoglycemia by automatic suspension of insulin delivery: the in-clinic ASPIRE study. Diabetes Tech Ther. 2012;14(3):205-209.

14. Battelino T et al. The SWITCH Study. Pediatric Diabetes 2011 Diabetologia DOI 10.1007/s00125-012-2708-9 Epub ahead of print and Aspire In-Home

21. “Thinks” refers to the data retrieval, processing and computing capabilities found in the MiniMed® 640G insulin pump, continuous glucose monitoring system (Guardian™ 2 Link and Enlite™ sensor), Contour® Next LINK 2.4 blood glucose meter and Medtronic CareLink® therapy management software, both collectively and individually. This system and its computing capabilities are part of, but not replacement for, your daily diabetes management. A confirmatory fingerstick is still required prior to making adjustments to diabetes therapy.

22. Within 30 minutes of event, both Low Glucose Limit and Low Predictive alerts ON; with 31 percent false alert rate, calibrating 3-4 times daily. Enlite Sensor Performance Report. Data on file. Northridge, CA.

23. U.S. Enlite Clinical Study Customer Satisfaction Survey. Data on file, Medtronic MiniMed, Inc., Northridge, CA.

24. Danne T et al. Prevention of hypoglycemia by using low glucose suspend function in sensor-augmented pump therapy. Diabetes Technology and Therapeutics 2011;13(11):1129-34

25. The dynamic suspend feature is based on certain criteria: sensor glucose must be within 3.9 mmol/L above the preset low limit and predicted to be no more than 1.1 mmol/L above the low limit within 30 minutes AND the pump must not be in the refractory period.

26. The dynamic resume feature is based on certain preset criteria: sensor glucose must be at least 1.1 mmol/L above the preset low limit and predicted to be greater than 2.2mmol/L above within 30 minutes AND insulin must have been suspended for at least 30 minutes.

27. User evaluations. Data on file, Medtronic MiniMed, Inc., Northridge, CA.